Get the Stockscreener App
2.86
0.35%
0.010
Pre-market:
2.87
0.01
+0.35%
Lipella Pharmaceuticals Inc stock is traded at $2.86, with a volume of 19,055.
It is up +0.35% in the last 24 hours and up +9.58% over the past month.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
See More
Previous Close:
$2.85
Open:
$2.86
24h Volume:
19,055
Relative Volume:
0.10
Market Cap:
$3.46M
Revenue:
-
Net Income/Loss:
$-4.74M
P/E Ratio:
-3.8133
EPS:
-0.75
Net Cash Flow:
$-3.46M
1W Performance:
-6.11%
1M Performance:
+9.58%
6M Performance:
-21.79%
1Y Performance:
-62.76%
1-Day Range:
$2.85
$2.92
1-Week Range:
$2.80
$3.15
52-Week Range:
$2.21
$12.00
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
Name
Lipella Pharmaceuticals Inc
Sector
Industry
Phone
412-901-0315
Address
400 N LEXINGTON ST, PITTSBURGH
Compare LIPO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.86 | 3.46M | 0 | -4.74M | -3.46M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lipella Pharmaceuticals Inc Stock (LIPO) Latest News
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 - MSN
Lipella Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com South Africa
Lipella Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement - GlobeNewswire Inc.
Lipella Pharmaceuticals Inc. Announces Second Closing of Offering 2024 - Defense World
SABBY MANAGEMENT, LLC Acquires 60,325 Shares in Lipella Pharmace - GuruFocus.com
Lipella Pharmaceuticals Inc. Enters into Agreement with Spartan Capital Securities, LLC and Closes Initial OfferingThe pharmaceutical company Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) recently disclosed in an 8-K filing with the U.S. Securities and - Defense World
Lipella Pharmaceuticals Cancels Special Meeting Due to Lack of Quorum - Defense World
Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times
Lipella Pharmaceuticals Enters into Placement Agent and Consulting Agreements - Defense World
Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com
Lipella Pharmaceuticals reschedules special meeting - Investing.com
Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan
Critical Review: Lipella Pharmaceuticals (LIPO) & Its Peers - Defense World
Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
Lipella Pharmaceuticals Inc (LIPO) Quarterly 10-Q Report - Quartzy
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipella issued patent by USPTO for liposomal drug delivery platform - TipRanks
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform - The Manila Times
Lipella Pharmaceuticals Secures Extended Market Exclusivity - GlobeNewswire
Lipella Pharma Secures Key Patent for Liposomal Platform, Extends Drug Pipeline Protection to 2035 | LIPO Stock News - StockTitan
China chip index nears 3-year high as TSMC order fuels self-reliance bets - Investing.com
Cathay general bancorp vice chairman sells $2.11 million in stock - Investing.com
Contrasting Wellness Center USA (OTCMKTS:WCUI) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Lipella Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com Australia
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - citybiz
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals announces 1-for-8 reverse stock split By Investing.com - Investing.com UK
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals Inc Stock (LIPO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):